Published in Vasc Health Risk Manag on October 07, 2013
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med (2001) 17.24
2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens (2003) 12.49
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med (2001) 10.36
Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA (2003) 9.06
Angiotensin II type 1 receptor blockers. Circulation (2001) 2.09
Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators. Am J Hypertens (1998) 1.85
Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens (Greenwich) (2001) 1.59
An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan. Irbesartan/Losartan Study Investigators. Clin Ther (1998) 1.54
Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in older vs younger patients with hypertension uncontrolled with monotherapy. Am J Geriatr Cardiol (2008) 1.48
Irbesartan reduces the albumin excretion rate in microalbuminuric type 2 diabetic patients independently of hypertension: a randomized double-blind placebo-controlled crossover study. Diabetes Care (2002) 1.08
Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin Pharmacol Ther (1995) 1.05
Oral bioavailability and disposition characteristics of irbesartan, an angiotensin antagonist, in healthy volunteers. J Clin Pharmacol (1998) 1.05
The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension. Clin Ther (1997) 1.03
The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial. J Clin Hypertens (Greenwich) (2005) 1.02
Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension. Am J Hypertens (1999) 1.01
The pharmacokinetics of irbesartan in hypertensive children and adolescents. J Clin Pharmacol (2001) 1.00
An ambulatory blood pressure monitoring study of the comparative antihypertensive efficacy of two angiotensin II receptor antagonists, irbesartan and valsartan. Blood Press Monit (2002) 0.99
A home blood pressure monitoring study comparing the antihypertensive efficacy of two angiotensin II receptor antagonist fixed combinations. Am J Hypertens (2005) 0.99
Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension. Am J Hypertens (1998) 0.98
Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens (2001) 0.95
Efficacy and safety of irbesartan/HCTZ combination therapy as initial treatment for rapid control of severe hypertension. J Clin Hypertens (Greenwich) (2006) 0.91
Angiotensin II receptor blockade in normotensive subjects: A direct comparison of three AT1 receptor antagonists. Hypertension (1999) 0.91
Pharmacokinetics and pharmacodynamics of irbesartan in healthy subjects. J Clin Pharmacol (1998) 0.90
The new angiotensin II receptor antagonist, irbesartan: pharmacokinetic and pharmacodynamic considerations. Am J Hypertens (1997) 0.89
A randomised, double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertension. J Hum Hypertens (1998) 0.89
A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension (1995) 0.86
Valsartan, a new angiotensin II antagonist: antihypertensive effects over 24 hours. Clin Ther (1997) 0.86
A comparison of the efficacy and safety of irbesartan/HCTZ combination therapy with irbesartan and HCTZ monotherapy in the treatment of moderate hypertension. J Hum Hypertens (2007) 0.86
Ambulatory blood pressure comparison of the anti-hypertensive efficacy of fixed combinations of irbesartan/hydrochlorothiazide and losartan/hydrochlorothiazide in patients with mild-to-moderate hypertension. J Int Med Res (2005) 0.86
Initial combination therapy with irbesartan/hydrochlorothiazide for hypertension: an analysis of the relationship between baseline blood pressure and the need for combination therapy. J Clin Hypertens (Greenwich) (2007) 0.86
Pharmacokinetics, disposition and biotransformation of [14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose. Xenobiotica (1997) 0.86
Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril. J Hypertens (1996) 0.86
Effects and tolerability of irbesartan versus enalapril in patients with severe hypertension. Irbesartan Multicenter Investigators. Am J Cardiol (1997) 0.85
The long-term antihypertensive activity and tolerability of irbesartan with hydrochlorothiazide. J Hum Hypertens (1999) 0.84
The effects of irbesartan added to hydrochlorothiazide for the treatment of hypertension in patients non-responsive to hydrochlorothiazide alone. J Clin Pharm Ther (1998) 0.83
Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in hypertensive women: the inclusive trial. J Womens Health (Larchmt) (2008) 0.83
Pharmacokinetics and pharmacodynamics of irbesartan in patients with hepatic cirrhosis. J Clin Pharmacol (1998) 0.83
A multicenter, randomized, double-blind study of the antihypertensive efficacy and tolerability of irbesartan in patients aged > or = 65 years with mild to moderate hypertension. Clin Ther (2000) 0.82
Comparative effects of irbesartan versus amlodipine on left ventricular mass index in hypertensive patients with left ventricular hypertrophy. J Cardiovasc Pharmacol (2003) 0.82
An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting. J Hum Hypertens (2004) 0.82
Cost-effectiveness of irbesartan 300 mg given early versus late in patients with hypertension and a history of type 2 diabetes and renal disease: a Canadian perspective. Clin Ther (2007) 0.82
Cost-effectiveness of irbesartan/hydrochlorothiazide in patients with hypertension: an economic evaluation for Sweden. J Hum Hypertens (2008) 0.81
24-hour blood pressure control by once-daily administration of irbesartan assessed by ambulatory blood pressure monitoring. Irbesartan Multicenter Investigators' Group. J Hypertens (1997) 0.81
The antihypertensive efficacy of the combination of irbesartan and hydrochlorothiazide assessed by 24-hour ambulatory blood pressure monitoring. Irbesartan Multicenter Study Group. Clin Exp Hypertens (1999) 0.81
Blood pressure effects of the angiotensin II receptor blocker, losartan. Arch Intern Med (1995) 0.81
An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings. Nephrol Dial Transplant (2003) 0.81
Irbesartan is projected to be cost and life saving in a Spanish setting for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria. Kidney Int Suppl (2005) 0.81
The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy. Clin Ther (2003) 0.80
Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension. J Hypertens (1995) 0.80
Renal response to the angiotensin II receptor subtype 1 antagonist irbesartan versus enalapril in hypertensive patients. J Hypertens (1998) 0.80
Biotransformation of irbesartan in man. Drug Metab Dispos (1998) 0.79
Irbesartan treatment of patients with type 2 diabetes, hypertension and renal disease: a UK health economics analysis. Int J Clin Pract (2007) 0.79
Health economic implications of irbesartan treatment versus standard blood pressure control in patients with type 2 diabetes, hypertension and renal disease: a Hungarian analysis. Eur J Health Econ (2007) 0.79
Efficacy and safety of irbesartan/HCTZ in severe hypertension according to cardiometabolic factors. J Clin Hypertens (Greenwich) (2010) 0.79
Efficacy and safety of two treatment combinations of hypertension in very elderly patients. Arch Gerontol Geriatr (2008) 0.79
Efficacy and safety of a fixed combination of irbesartan/hydrochlorothiazide in Chinese patients with moderate to severe hypertension. Drugs R D (2013) 0.79
[Irbesartan in hypertensive non-diabetic advanced chronic kidney disease. Comparative study with ACEI]. Nefrologia (2008) 0.79
Randomized, double-blind comparison of irbesartan and enalapril for treatment of mild to moderate hypertension. Zhonghua Yi Xue Za Zhi (Taipei) (2000) 0.78
Role of cytochrome P-4502C9 in irbesartan oxidation by human liver microsomes. Drug Metab Dispos (1999) 0.78
The effects of age and gender on the pharmacokinetics of irbesartan. Br J Clin Pharmacol (1998) 0.78
Irbesartan and atenolol improve diastolic function in patients with hypertensive left ventricular hypertrophy. J Hypertens (2005) 0.78
Comparison of monotherapy with irbesartan 150 mg or amlodipine 5 mg for treatment of mild-to-moderate hypertension. J Renin Angiotensin Aldosterone Syst (2005) 0.78
Acute renal effects of AT1-receptor blockade after exogenous angiotensin II infusion in healthy subjects. J Cardiovasc Pharmacol (1998) 0.78
Efficacy, tolerability, and quality of life of losartan, alone or with hydrochlorothiazide, versus nifedipine GITS in patients with essential hypertension. Clin Ther (1996) 0.78
Economic evaluation of irbesartan in combination with hydrochlorothiazide in the treatment of hypertension in Greece. Eur J Health Econ (2010) 0.78
The pharmacokinetics of irbesartan in renal failure and maintenance hemodialysis. Clin Pharmacol Ther (1997) 0.77
Economic evaluation of the use of irbesartan and amlodipine in the treatment of diabetic nephropathy in patients with hypertension in Canada. Can J Cardiol (2004) 0.77
Irbesartan/hydrochlorothiazide for the treatment of isolated systolic hypertension: a subgroup analysis of the INCLUSIVE trial. J Natl Med Assoc (2009) 0.77
A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension. Curr Med Res Opin (2006) 0.77
A randomized trial of the effect of an angiotensin II receptor blocker SR47436 (irbesartan) on 24-hour blood pressure in patients with essential hypertension. Hypertens Res (2008) 0.76
The KARTAN study: a postmarketing assessment of Irbesartan in patients with hypertension. Clin Ther (2004) 0.76
Pharmacokinetics of irbesartan are not altered in special populations. J Cardiovasc Pharmacol (2002) 0.76
Pharmacodynamics and Pharmacokinetics of Irbesartan in Patients With Mild to Moderate Hypertension. J Cardiovasc Pharmacol Ther (1999) 0.76
Comparison of the angiotensin II receptor antagonist irbesartan with atenolol for treatment of hypertension. Blood Press (1998) 0.76
Irbesartan does not affect the pharmacokinetics of simvastatin in healthy subjects. J Clin Pharmacol (2000) 0.76
Microalbuminuria in hypertensive patients: evaluation of one-year treatment with irbesartan. Kidney Int Suppl (2005) 0.76
Comparative effects of combination drug therapy regimens commencing with either losartan potassium, an angiotensin II receptor antagonist, or enalapril maleate for the treatment of severe hypertension. J Hypertens (1996) 0.76
The pharmacokinetics and pharmacodynamics of irbesartan in heart failure. J Clin Pharmacol (2001) 0.76
Health economic implications of irbesartan plus conventional antihypertensive medications versus conventional blood pressure control alone in patients with type 2 diabetes, hypertension, and renal disease in Switzerland. Swiss Med Wkly (2006) 0.76
Regression of microalbuminuria in type 2 diabetics after switch to irbesartan treatment : an observational study in 38 016 patients in primary care. Clin Drug Investig (2004) 0.75
Irbesartan does not affect the steady-state pharmacodynamics and pharmacokinetics of warfarin. Eur J Clin Pharmacol (1999) 0.75
Comparative efficacy of irbesartan/ hydrochlorothiazide and valsartan/hydrochlorothiazide combination in lowering blood pressure: a retrospective observational study in Oman. Med Princ Pract (2012) 0.75
Factors influencing prescribing behaviour of physicians in Greece and Cyprus: results from a questionnaire based survey. BMC Health Serv Res (2009) 1.35
Photoselective GreenLight™ laser vaporization versus transurethral resection of the prostate in Greece: a comparative cost analysis. J Endourol (2011) 1.00
Patient preference and willingness-to-pay for Humalog Mix25 relative to Humulin 30/70: a multicountry application of a discrete choice experiment. Value Health (2004) 0.93
Pharmacoeconomic considerations in the treatment of breast cancer. Clinicoecon Outcomes Res (2010) 0.92
Cost-effectiveness of atrial fibrillation catheter ablation. Europace (2008) 0.88
Economic evaluation of gemcitabine in the treatment of pancreatic cancer in the UK. Eur J Health Econ (2003) 0.87
Survival from breast cancer in relation to access to tertiary healthcare, body mass index, tumor characteristics and treatment: a Hellenic Cooperative Oncology Group (HeCOG) study. Eur J Epidemiol (2012) 0.87
Comparison of filgrastim and pegfilgrastim to prevent neutropenia and maintain dose intensity of adjuvant chemotherapy in patients with breast cancer. Support Care Cancer (2014) 0.85
Physicians' perceptions and adherence to guidelines for the management of hypertension: a national, multicentre, prospective study. Int J Hypertens (2012) 0.85
Device therapy and hospital reimbursement practices across European countries: a heterogeneous scenario. Europace (2011) 0.84
Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled Type 2 diabetes on oral antidiabetic drugs in Greece. BMC Health Serv Res (2014) 0.84
Health technology assessment in interventional electrophysiology and device therapy: a position paper of the European Heart Rhythm Association. Eur Heart J (2013) 0.83
Health economics and outcomes research: a new challenge and field of action for the European Heart Rhythm Association. Europace (2010) 0.82
Costs and effects of various analgesic treatments for patients with rheumatoid arthritis and osteoarthritis in the Netherlands. Value Health (2008) 0.81
Factors associated with the use of pap smear testing in Greece. J Womens Health (Larchmt) (2010) 0.81
Retrospective cost analysis of gemcitabine in combination with cisplatin in non-small cell lung cancer compared to other combination therapies in Europe. Lung Cancer (2004) 0.81
The public's and doctors' perceived role in participation in setting health care priorities in Greece. Hellenic J Cardiol (2010) 0.81
Factors associated with the use of preventive services by women in Greece. Eur J Public Health (2010) 0.80
Economic evaluation of ivabradine in the treatment of chronic heart failure in Greece. BMC Health Serv Res (2014) 0.80
The humanistic and economic burden of venous thromboembolism in cancer patients: a systematic review. Blood Coagul Fibrinolysis (2015) 0.79
The cost effectiveness of implantable cardioverter defibrillators: a systematic review of economic evaluations. Appl Health Econ Health Policy (2014) 0.79
Quality of life measurement in patients with hypertension in Cyprus. Hellenic J Cardiol (2011) 0.78
Clopidogrel versus aspirin in patients with atherothrombosis: a CAPRIE-based cost-effectiveness model for Greece. Appl Health Econ Health Policy (2012) 0.77
Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis. Appl Health Econ Health Policy (2012) 0.77
Analysis of published economic evaluations of angiotensin receptor blockers. Hellenic J Cardiol (2009) 0.77
Economic evaluation of rivaroxaban in stroke prevention for patients with atrial fibrillation in Greece. Cost Eff Resour Alloc (2014) 0.76
Atrial fibrillation ablation: a cost or an investment? Europace (2011) 0.76
Early evaluation of an organised mammography screening program in Greece 2004-2009. Cancer Epidemiol (2011) 0.76
Cost effectiveness of treatments for non-ST-segment elevation acute coronary syndrome. Pharmacoeconomics (2014) 0.75
Health technology assessment: what is it? Current status and perspectives in the field of electrophysiology. Europace (2011) 0.75
Economic evaluation of dabigatran etexilate in the management of atrial fibrillation in Greece. Hellenic J Cardiol (2013) 0.75